Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Theta-Burst-Stimulation in Early Rehabilitation of Stroke (TheSiReS)

19. september 2022 oppdatert av: Gereon R. Fink, University of Cologne

Theta-Burst-Stimulation in Der frühen Rehabilitation Von Schlaganfallpatienten

The present prospective, randomized, controlled, double-blinded trial investigates the effects of intermittent theta-burst stimulation (iTBS) during the early rehabilitation after stroke. Patients with hemipresis will receive either sham or real iTBS over their affected hemispheres before occupational therapy for 8 days. Motor recovery is assessed one day after the intervention phase and three months after enrollment.

Studieoversikt

Detaljert beskrivelse

To date, rehabilitation of stroke with hemiparesis mainly includes physiotherapy and occupational therapy. Yet, the majority of patients retain movement impairment relevant for activities of daily living. One explanation for this deficit is the insufficient recovery of connectivity between brain regions after stroke. It is possible to modulate this process by repetitive transcranial magnetic stimulation (rTMS) using the protocol of intermittent theta-burst stimulation (iTBS). Previous data indicate that modulation of the motor cortex with iTBS enhances the effects of subsequent motor training. The present study aims at investigating whether daily repetitive transcranial magnetic stimulation over 8 days combined with subsequent physiotherapy leads to better motor recovery, compared with physiotherapy after sham stimulation. In the first weeks and after three months, motor function, degree of disability and quality of life are examined in order to evaluate the effects of iTBS in the rehabilitation of stroke patients.

Amendment (approved by the Ethics-Committee of the Medical Faculty of the University of Cologne, 20/12/2016): Specification of exclusion criteria.

Amendment (approved by the Ethics-Committee of the Medical Faculty of the University of Cologne, 15/11/2018): Change of inclusion and exclusion criteria.

Studietype

Intervensjonell

Registrering (Faktiske)

150

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Tyskland, 50924
        • Klinik und Poliklinik für Neurologie, Universitätsklinikum Köln

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

40 år til 90 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • written consent
  • age: 40-90 years
  • ischemic stroke
  • hemiparesis with impaired hand motor function

Exclusion Criteria:

  • Subjects who are legally detained in an official institute (§20 MPG)
  • Participation in clinical trial within the last 12 weeks
  • Electronic implants or ferromagnetic Implants located in the head, neck or thorax (e.g. clips, intracranial shunt, artificial heart valve, pacemaker)
  • Medication pump (e.g. insulin pump)
  • Metal splinters in eye or head
  • Pregnancy / breastfeeding
  • Severe Neurodegenerative disease
  • Severe Neuroinflammatory disease
  • History of seizures / epilepsy
  • Physical addiction to alcohol, medication, or drugs (excluded: nicotine)
  • Insufficient compliance
  • Present or past malignant tumor involving the central nervous system
  • Severe Psychiatric disease
  • Clinically manifest bilateral hemiparesis or infarcts in the primary motor cortex or along the tractus corticospinalis in the hemisphere ipsilateral to the hemiparesis
  • Pre-existing cerebral infarctions with hemiparesis or pre-existing cerebral infarctions in the primary motor cortex or along the tractus corticospinalis, excluding microangiopathic changes (e.g. clinically asymptomatic lacunae <1cm)
  • Known brain lesion (surgical, traumatic)
  • Evidence for enhanced cerebral pressure
  • Severe cardial dysfunction
  • life expectancy < 12 months
  • NIHSS Score > 20
  • Blood glucose imbalances resistant to treatment (<50 mg/dl or >300 mg/dl)
  • Elevated blood pressure resistant to treatment (RR > 185/110mmHg)
  • Systemic Thrombolysis using r-tPA or thrombectomy within the last 24 hours before enrollment in study
  • Medication with benzodiazepines, high-potency antipsychotics or tricyclic antidepressants before hospitalization or long-term during hospitalization

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Real-rTMS
Repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex in the lesioned hemisphere using the intermittent theta-burst-stimulation protocol (iTBS; application of 3 pulses with a frequency of 50 Hz, in a theta-rhythm of 5 Hz for 2 seconds, repeated every 10 seconds, duration of one session: about 3,5 minutes) before physiotherapy for 8 days
iTBS applied over ipsilesional M1
Sham-komparator: Sham-rTMS
Repetitive transcranial magnetic stimulation (rTMS) in sham position (tilted coil over parieto-occipital vertex) before physiotherapy for 8 days
iTBS applied with tilted coil over parieto-occipital vertex

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Relative grip force
Tidsramme: 3 months after enrollment
grip force as measured with vigorimeter
3 months after enrollment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Days of rehabilitation after intervention phase
Tidsramme: 3 months after enrollment
Days of rehabilitation after intervention phase as documented by external rehabilitation facility
3 months after enrollment
Relative grip force
Tidsramme: after 8 days of intervention, and 3 months after enrollment
grip force as measured with vigorimeter
after 8 days of intervention, and 3 months after enrollment
Motor function
Tidsramme: after 8 days of intervention, and 3 months after enrollment
Action Research Arm Test, ARAT
after 8 days of intervention, and 3 months after enrollment
Motor function
Tidsramme: after 8 days of intervention, and 3 months after enrollment
Fugl-Meyer Motor Scale of the upper extremity, FM
after 8 days of intervention, and 3 months after enrollment
Stroke severity
Tidsramme: after 8 days of intervention, and 3 months after enrollment
National Instituts of Health Stroke Scale, NIHSS
after 8 days of intervention, and 3 months after enrollment
Degree of disability
Tidsramme: after 8 days of intervention, and 3 months after enrollment
modified Rankin Scale, mRS
after 8 days of intervention, and 3 months after enrollment
Motorcortex excitability
Tidsramme: after 8 days of intervention, and 3 months after enrollment
Motor evoked potential induced by stimulation of the affected motor cortex, MEP
after 8 days of intervention, and 3 months after enrollment
Motorcortex excitability
Tidsramme: after 8 days of intervention, and 3 months after enrollment
Resting motor threshold as measured by stimulation of the affected motor cortex, RMT
after 8 days of intervention, and 3 months after enrollment
Quality of life
Tidsramme: after 8 days of intervention, and 3 months after enrollment
EuroQol 5D questionnaire, EQ-5D
after 8 days of intervention, and 3 months after enrollment
Activities of daily living at admission and discharge in external rehabilitation facility
Tidsramme: 3 months after enrollment
Barthel-Index (BI) scores as documented by external rehabilitation facility
3 months after enrollment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Gereon R Fink, Univ.-Prof. Dr., University of Cologne

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. april 2016

Primær fullføring (Faktiske)

15. september 2022

Studiet fullført (Faktiske)

15. september 2022

Datoer for studieregistrering

Først innsendt

8. september 2016

Først innsendt som oppfylte QC-kriteriene

19. september 2016

Først lagt ut (Anslag)

21. september 2016

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

21. september 2022

Siste oppdatering sendt inn som oppfylte QC-kriteriene

19. september 2022

Sist bekreftet

1. september 2022

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • Uni-Koeln-1778
  • U1111-1172-6026 (Annen identifikator: WHO)
  • CIV-15-09-013868 (Annen identifikator: EUDAMED)
  • DRKS00008963 (Registeridentifikator: DRKS)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

3
Abonnere